Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background According to the amyloid, tau, neurodegeneration research framework classification, amyloid and tau positive (A+T+) mild cognitive impairment (MCI) individuals are defined as prodromal Alzheimer disease. This study was designed to compare the clinical and biomarker features between A+T+MCI individuals who progressed to progressive MCI (pMCI) and those who remained stable MCI (sMCI), and to identify relevant baseline clinical biomarker and features that could be used to predict progression to dementia within 2 years. Methods We stratified 197 A+T+MCI individuals into pMCI (n = 64) and sMCI (n = 133) over 2 years.

What this study adds

Evidence grade: Low

The record lists 64 participants. This study compared clinical and biomarker features between people with mild cognitive impairment who progressed to dementia and those who remained stable, to identify predictors of progression within 2 years. It is an observational study and does not test any treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wei, H. C., Li, B., Ng, K. P., Fu, Q. X., Dong, S. J., Ba, M. W., et al. (2021). Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression. Chinese medical journal. https://doi.org/10.1097/cm9.0000000000001496

Vancouver

Wei HC, Li B, Ng KP, Fu QX, Dong SJ, Ba MW, et al. Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression. Chinese medical journal. 2021. doi:10.1097/cm9.0000000000001496. PMID: 34397597.

BibTeX

@article{wei2021-34397597,
  author  = {Wei, H. C. and Li, B. and Ng, K. P. and Fu, Q. X. and Dong, S. J. and Ba, M. W. and Kong, M.},
  title   = {{Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression}},
  journal = {Chinese medical journal},
  year    = {2021},
  doi     = {10.1097/cm9.0000000000001496},
  pmid    = {34397597},
  url     = {https://doi.org/10.1097/cm9.0000000000001496}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study compared clinical and biomarker features between people with mild cognitive impairment who progressed to dementia and those who remained stable, to identify predictors of progression within 2 years. It is an observational study and does not test any treatment or cure.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 39 of 100.39 of 100 points earned61 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Chinese medical journal)
Journal's citation record 1 / 4 Chinese Medical Journal: journal h-index 94 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 1 / 4 64 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 10 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.4 citations a year over 7 year(s) since 2021
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Min Kong: h-index 13 (OpenAlex, whole career)
Institution's track record 0 / 3 Qingdao University: institution h-index 430 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34397597)
Free to read 2 / 2 Free to read
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →